# GV20 Therapeutics

Source: https://onco.cc/companies/gv20-therapeutics/  
OnCo record `gv20-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GV20 Therapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the anti-IGSF8 antibody GV20-0251 in endometrial cancer, head and neck squamous cell carcinoma, melanoma and non-small-cell lung cancer.

## Summary

GV20 Therapeutics is a clinical-stage biotechnology company that uses its AI-driven STEAD platform, combining B-cell repertoire data, omics data and disease biology, to discover antibody targets and therapeutics. Its lead candidate GV20-0251 is a first-in-class antibody against the immune checkpoint IGSF8, in phase 1 in the United States and China. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT05669430 (phase 1/2, A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Par...) and NCT07070518 (phase 1/2, Study of GV20-0251 in Participants With Solid Tumor Malignancies). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: GV20 Therapeutics
- Tags: ctgov-sponsor
- HQ: Newton, Massachusetts
- Type: biotech
- Website: https://gv20tx.com

## Sources

- Official website: https://gv20tx.com
- ClinicalTrials.gov: trials led by GV20 Therapeutics: https://clinicaltrials.gov/search?lead=GV20%20Therapeutics

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- trials: [A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies](https://onco.cc/trials/nct05669430/), [Study of GV20-0251 in Participants With Solid Tumor Malignancies](https://onco.cc/trials/nct07070518/)

---
JSON: https://onco.cc/api/v1/entities/gv20-therapeutics.json